New drug shows promise for brain function in Huntington's patients

NCT ID NCT05358821

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tested a drug called SAGE-718 in 69 people with early Huntington's disease to see if it could improve thinking and daily functioning. Participants took the drug or a placebo for 28 days. The main goal was to measure changes in cognitive abilities like memory and problem-solving compared to healthy volunteers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Sage Investigational Site

    Birmingham, Alabama, 35233, United States

  • Sage Investigational Site

    Los Alamitos, California, 90720, United States

  • Sage Investigational Site

    Englewood, Colorado, 80113, United States

  • Sage Investigational Site

    Washington D.C., District of Columbia, 20057, United States

  • Sage Investigational Site

    Boca Raton, Florida, 33431, United States

  • Sage Investigational Site

    Tampa, Florida, 33602, United States

  • Sage Investigational Site

    Chicago, Illinois, 60612, United States

  • Sage Investigational Site

    Baltimore, Maryland, 21218, United States

  • Sage Investigational Site

    New York, New York, 10027, United States

  • Sage Investigational Site

    Chapel Hill, North Carolina, 27599, United States

  • Sage Investigational Site

    Cincinnati, Ohio, 45221, United States

  • Sage Investigational Site

    Philadelphia, Pennsylvania, 19104, United States

  • Sage Investigational Site

    Houston, Texas, 77030, United States

  • Sage Investigational Site

    Montreal, H2X 3E4, Canada

Conditions

Explore the condition pages connected to this study.